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INTRODUCTION 
Malignancy of breast is a worldwide major health problem. . 
Every year more than a million women are newly diagnosed as 
carcinoma of breast. Due to advances in medical science the mortality 
from the carcinoma breast is beginning to fall because of early 
diagnosis and improved treatment facilities.[1] From various studies it 
is established that breast cancer is rare before the age of 25 years, but 
incidence increases with age from the third decade of life.[94] 
Carcinoma of breast is seen most commonly in females of 
reproductive age groups, but risk of developing breast carcinoma is 
increased with age. In males it is very rare . The incidence of breast 
carcinoma in male is less than 1%. The pathogenesis of breast 
carcinoma is multifactorial, depending on a combination of genetic 
factor, race ,family history, reproductive history etc. 
Most of the malignant tumors of breast are adenocarcinomas     
(more than 95% cases). They first arise from duct or lobular system 
from the precursor lesions (carcinoma in situ).[94] Malignant stromal 
tumor can also occur in breast. Angiosarcoma is the commonest 
stromal malignancy in breast. Other stromal malignant lesions of 
breast are malignant phyllodes tumor, Rhabdomyosarcoma, 
liposarcoma, leiomyosarcoma, chondrosarcoma and osteosarcoma.[94] 
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Morphologically malignant lesions of breast tissue are divided on the 
basis of  2 characteristics’   
(1) Depending on invasion in to the stroma 
In situ carcinoma tumors are confined to the epithelial 
component. Invasion of  the stroma by the tumor component is  
termed as invasive carcinoma. 
(2) Whether it is ductal or lobular type[18] 
For diagnosis of malignant tumor of breast, the  lesions should 
be examined clinically, radiologically and by tissue sampling. The 
combination of these three is termed as triple assessment. 
Mammography and ultrasonography are the most commonly used 
radiological test for screening of breast carcinoma. Now a days many 
breast carcinoma cases are detected early by using mammogram.  
Most common symptoms of carcinoma breast is  breast lump, with or 
without pain. Other symptoms are nipple discharge, nipple retraction 
or eczema mayalso occur.[95] 
Like other malignant tumors, the prognosis of  breast carcinoma 
also depends upon various factors, like age, tumor size, histologic 
grade, invasiveness, metastasis, molecular subtype etc. Breast 
carcinomas expressing estrogen receptor (ER) and progesterone 
receptor (PR) have excellent response to hormonal therapy. 
Expression of HER-2 is associated with poor prognostic outcome. 
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Some recent studies show that expression of GATA-3 gene is 
associated with good prognosis and survival in breast carcinoma 
patients. Few other studies has shown that expression of GATA-3 is 
limited to carcinoma of breast and carcinoma of urinary bladder and 
therefore this immunohistochemical marker may be a sensitive and 
specific marker for metastatic breast carcinomas particularly for those 
tumors which have lack of specific markers to prove mammary   
origin.[96] 
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AIMS & OBJECTIVES 
To evaluate the expression of GATA-3 in breast carcinoma by 
using Mouse monoclonal antibody. 
To compare the GATA-3 expression with already known ER, 
PR and HER 2 neu status of breast carcinoma cases. 
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REVIEW OF LITERATURE 
 
EPIDEMIOLOGY 
Breast carcinoma is the second most common malignancy  after 
carcinoma lung worldwide.  Among the women it is the most common 
cancer in the globe, contributing 25.4 % of total number of newly 
diagnosed cancer cases. [2] 
It is rare in women below the age of 25 years but, after  the age 
of 30 years the incidence increases rapidly. According to the Indian 
cancer, registry data carcinoma breast is the most common malignant 
tumor among the Indian ladies. The rate of incidence is 25.8 per 
100,000 Indian women. Mortality from breast cancer is high in rural 
registries  than urban  registries of India. [3] 
 
RISK FACTORS 
For the development of breast carcinoma action of several risk 
factors have been well proved, and many others are yet to be 
established. [4] 
1. Gender: Female gender is itself a risk factor of developing breast 
carcinoma. Approximately 99% of the breast carcinoma patients 
are female. 
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2. Age: Age is also a risk factor of breast carcinoma. Risk of 
developing breast carcinoma is increased with age . 
3. Geographical Location: The incidence of Ca breast is high in 
western world  (91.4 new cases per 100 000 women/year), but 
low in Asian and African countries. 
4. Race/Ethnicity: Incidence of breast cancer are higher among the 
whites than other racial and ethnic groups. 
5. Family History: Women who have a history of breast carcinoma 
in first-degree relatives are at 2 to 3 times higher risk than the 
general population. The most known susceptible  genes for 
familial breast cancer are tumor suppressor genes BRCA1, 
BRCA2, TP53, and CHEK2.  Approximately 3% of all breast 
cancers are due to mutations in BRCA1 (chromosome 17q21) 
and BRCA2 (chromosome13q12.3) . 
6. Reproductive History: Breast Carcinoma is high among the 
women with early menarche, late menopause, nulliparity and  
late age at first  child birth.  Oophorectomized ladies before the 
age of  35 years have reduced incidence. Studies shows  that the 
ladies who attended menarche before the age of 11 years have 
20% increased risk of developing breast carcinoma than the 
ladies who attended menarche after the age of 14 years. 
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Pregnancy before the age of 20 years decreases the chances of  
developing breast carcinoma. 
7. Lactation history also plays an important role in reducing the 
incidence of breast carcinoma. 
8. Estrogens: Estrogen is also an important risk factor for breast 
carcinoma. Some recent studies shows that the  women who use  
hormone replacement therapy for a longer duration are 
associated with an increased risk of  carcinoma breast than in 
those who use estrogens alone. 
9. Carcinoma of the contralateral breast:  About 1% of the breast 
carcinoma patients may develop carcinoma in the another breast. 
10. Ionizing Radiation is also a risk factor for developing of breast 
carcinoma, particularly if the exposure get during the 
development of mammary gland. . 
11. Obesity: The obese ladies under 40 are at decreased risk of 
developing breast carcinoma because of anovulatory cycle in 
obese women and  low progesterone level. Otherwise 
postmenopausal obese womens have increased risk of 
developing breast carcinoma. 
12. Contraceptive: Various epidemiologic studies proved that use of 
contraceptive agent does not cause increased risk of developing 
breast carcinoma.  Some studies show that a very low increase of 
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incidence may be possible  among young ladies of long-term 
contraceptive users.[5] 
13. Toxins: Several toxins like pesticide organochloride may cause 
breast carcinoma. It is believed that organochloride  may have 
estrogenic effect in human body. 
14. Exercise: Physical exercise is protective against breast 
carcinoma. 
 
MALE BREAST CARCINOMA: 
Carcinoma of male breast is very rare, accounting only 1% of 
the cases.  Risk factors of male breast carcinoma are similar to the 
women’s. First degree relatives affected by carcinoma breast are at 
high risk group. The other  risk factors are age, exposure to exogenous 
estrogen, male infertility ( for example klinefelter syndrome), obesity, 
gynaecomastia etc . 
 
ANATOMY OF BREAST: 
Morphologically the breast is  a complex branching structure 
divided into multiple lobes . Each lobes is composed of 2 components: 
the terminal duct–lobular unit (TDLU) and the large duct system[6] the 
TDLU are the secretary unit of the gland  and is formed by the lobules 
and terminal ductules. the duct system of the mammary gland contains 
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sub segmental duct, segmental duct, and finally collecting duct 
(lactiferous duct).  
The large collecting ducts open into the surface of  the nipple 
through 5 to 9 orifices. Numerous sebaceous glands also open 
independently of  hair follicles. Ten to twenty. areolar protuberances 
called  montgomery tubercles are formed by a collecting (lactiferous) 
duct associated with a sebaceous apparatus.  These protuberances 
become prominent during pregnancy.[7] 
 
 
 
 
 
 
 
 
 
 
Fig: Diagram of breast morphology showing terminal duct–
lobular unit (TDLU) subsegmental duct, segmental duct, and 
finally collecting duct (lactiferous duct) 
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GENOMICS OF BREAST CANCER 
Total 5 to 10% of  breast carcinomas are  hereditary in origin. 
Some other studies show about twelve percent of  breast cancers are 
familial. 
From the literatures of recent studies, mutations of mainly two 
genes, namely BRCA1 and BRCA2, are responsible for  familial 
breast cancer. the gene BRCA1 is located on chromosome 17q21, and 
BRCA2,is located on 13q12.3. 
Several other genes also have been identified as cause of breast 
cancer development.  Hereditary breast cancer may  be associated with 
multiple cancer syndromes. Some common genes other than 
BRCA1,and BRCA2 are, fanconi anaemia (FANC) genes, CHK2, 
TP53 , and ATM tumour suppressor genes.[8] 
For the development of breast carcinoma three major pathways 
have been proposed.  First and most common pathway is germline 
mutation of BRCA 2 gene. These tumors are  mostly the ER positive 
cases. The Mutation of BRCA 2 gene cause flat epithelial atypia then 
leads to atypical hyperplasia which is the precursor lesion of 
developing breast carcinoma. 
Second  pathway is  germline mutation of gene TP53 gene and 
HER2 gene amplification leads to apocrine adenosis. Apocrine 
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adenosis is the precursor lesion for  ductal carcinoma in situ, cases of 
HER2c positive breast carcinoma cases. 
Third pathway is germline BRCA 1 mutation . In this group no  
precursor lesions have been established. These tumors are triple 
negative ( ER negative, PR negative, and HER 2 negative) also termed 
as basal like . 
 
DIAGNOSIS OF BREAST CANCER 
Apart from clinical examination, many other methods are 
practiced  for the detection and evaluation of breast disease. A 
combination of clinical examination, radiological and pathological 
examination is useful for diagnosis and management of breast cancer. 
 
Mammography: Mammogram is one of the most  suitable methods 
for screening of breast cancer. Screening of breast carcinoma with 
mammogram was introduced in the 1980s. By using mammography, 
extremely small tumors (1–2 mm) can also be detected in presence of 
calcification. Both the sensitivity and the specificity  of 
mammographic breast screening is increased with age. In 
mammographic screening two principal findings are observed, the 
breast density and calcification. Carcinomas usually shows irregular 
dense areas. Clustered numerous, small, irregular calcified areas are 
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associated with malignancy.  Mammographic findings are reported by 
using the Breast Imaging Reporting and Data System (BI-RADS) 
which is standardized by American College of Radiology (ACR) .[9] 
Other radiological tests for detection of breast carcinoma are 
ultrasonography and Magnetic resonance imaging (MRI). 
Ultrasonography is particularly helpful in separating solid from cystic 
lesions. Magnetic resonance imaging (MRI) is also a useful and 
effective technique for the breast cancer detection, diagnosis, and 
staging. [10] 
Cytology: 
For cytological detection of breast malignancy two methods that 
have been used.  FNAC (Fine needle aspiration cytology) is a method  
to obtain cytologic material from the lesion by aspirating with a fine 
needle. [11] 
The  Fine needle aspiration cytology procedure has many 
significant advantages   is the low cost and the ability conclude a 
diagnosis within a very short period of time. As it is a very less time 
consuming procedure the treatment decisions can be made 
immediately by the clinicians.[97] Material obtained from FNAC also 
can be used  for detection of hormone receptor (Estrogen receptor  & 
progesterone receptor),[12] oncoprotein expression.[449] and for kinetic 
studies.[13] 
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Another method of cytological test is imprint or aspiration of 
nipple secretion. 
 
HISTOPATHOLOGICAL EXAMINATION: 
The histopathological specimens of breast may be tur-cut 
biopsy. incisional biopsy or excisional biopsy,  lumpectomy specimen  
or quadrantectomy or mastectomy  (surgical removal of entire 
breast).[16] 
 
Needle biopsy: 
Biopsy is  performed with large core needle for palpable masses 
(Tru-Cut) without any radiologic guidance. [16] 
 
Open biopsy: 
Open excisional biopsy from breast lesions is usually used to do 
for the tumor measuring 2.5 cm or less in diameter and for larger 
neoplasms incisional type of biopsy is practiced. Advantages of open 
biopsy is that it is a very highly accurate procedure; very low false-
positive rate, (nearly zero), and false-negative rate  (less than 1%). 
[14,15] 
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Incisional Biopsy: 
Incisional biopsy of breast is very rarely practiced , almost 
always performed to evaluate unresectable malignant tumors of breast. 
Main aim of incisional biopsy is for confirmation of the clinical 
diagnosis and to know the ER, PR and HER2/neu status. [16] 
 
Excisional Biopsy: 
Complete removal of the lesion performed for  the primary 
evaluation of a breast lesion. [16] 
 
ANCILLARY STUDIES 
For proper treatment of breast carcinoma the status of   estrogen 
receptor (ER) and progesterone receptor (PR) status is also necessary. 
To know the ER and  PR receptor status,  Immunohistochemical (IHC) 
study is  most commonly used technique in modern medicine.[17] The 
most important advantage of IHC marker study to know the hormone 
receptor status is it requires a very small amount of specimen. 
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MICROSCOPIC TYPES OF BREAST CARCINOMA 
For morphological study of breast tissue two important points to 
be observed. 
(1) Invasion into the stroma:-- based on the invasion into 
the stroma, the breast lesions are divided into in situ 
carcinoma and invasive carcinoma. In situ carcinoma 
is defined as if the tumor is confined to the epithelial 
component. If the tumor has invaded the stroma then 
it is termed as invasive carcinoma. 
(2) Whether it is ductal or lobular type .[18] 
 
IN SITU CARCINOMA 
Ductal carcinoma in situ (DCIS): 
DCIS represents tumors that the proliferated malignant 
epithelial cells limited to the ducts or lobules within the basement 
membrane layer .   Variants of ductal carcinoma in situ  are subdivided 
according to morphologic patterns, such as papillary, micropapillary, 
comedo-DCIS, solid pattern, cribriform, cystic and clinging.[19] 
Among these subtypes the Papillary variant of DCIS  is believed, to be 
arised from larger ducts of breast and the other subtypes are, believed 
to originate  from  the  terminal duct–lobular unit (TDLU).[ 20] 
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Comedo DCIS:  
Charecterised by Pleomorphic cells with high grade nuclear 
morphology with central areas of necrosis. 
Noncomedo DCIS: 
In this pattern no  central areas of necrosis or no high grade 
nuclei 
. 
 
 
Fig: Comedo DCIS showing neoplastic cells within the basement 
membrane with central areas of necrosis. 
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Lobular carcinoma in situ (LCIS): 
Lobular carcinoma in situ lesions are incidental finding in 
breasts removed for other reasons  and they show similar features on 
gross examination.  About 70% of cases of LCIS are multicentric [21] 
and 30–40% of LCIS are bilateral.[22] 
Microscopic feature of  the LCIS show distended  lobules 
composed of relatively monomorphic , round to oval , small-to-
medium-sized cells with round  normochromatic nuclei. Sometimes 
the nuclei may be mild hyperchromatic[23] 
Usually mitotic activity and necrosis are absent or very 
minimal.[24]  Some LCIS cases are composed of  medium to large size 
tumor cells exhibiting  moderate to abundant cytoplasm with nuclear 
pleomorphism, and occasional prominent nucleoli. These  lesions are 
referred  as pleomorphic Lobular carcinoma in situ.[25] 
 
INVASIVE CARCINOMA: 
Tumors with detectable stromal invasion are termed as invasive 
carcinoma.  Invasive carcinomas are divided in to sub categories based 
on morphologic variant and molecular characteristics’. On the basis of 
morphology, invasive carcinoma can also be divided into two major 
subtypes – ductal type and lobular type, like the in-situ lesions. 
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MAJOR HISTOLOGIC TYPES OF INVASIVE BREAST 
CARCINOMA: 
IDC NST(Invasive ductal carcinoma no special type):  
IDC-NST is the most common histopathological type of breast 
carcinoma. Approximately 70 % to 75 % of breast carcinoma cases are 
IDC-NST type. Microscopic, features are variable from case to case. 
 
ILC ( invasive lobular carcinoma): 
It contributes  5 to 15 % of the total breast carcinoma cases. 
Microscopically, the tumour is composed of noncohesive cells with 
eccentrically placed nuclei arranged in Indian file and targetoid 
pattern. These tumors are mostly estrogen receptor (ER) and 
progesterone receptor (PR) positive but HER 2 negative. 
 
Invasive Tubular carcinoma: 
Total 5% of the invasive carcinomas are tubular carcinoma. 
Prognosis of this type is good because of low metastatic potential. 
Microscopically, tumor is composed of angulated tubules in haphazard 
arrangement lined by single layered of malignant epithelial cells 
eosinophilic to amphophilic cytoplasm with pleomorphic oval nuclei.  
Most of the tumors are Estrogen   Receptor  and  Progesterone 
Receptor positive . 
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Invasive Mucinous carcinoma: 
Another histological variant of breast carcinoma contributing 
approximately 2% to 3% of breast carcinoma cases. Grossly tumor is 
well circumscribed lobulated mass with gelatinous cut surface. 
Microscopically, neoplastic cells are seen floating in pools of 
extracellular mucin. Most of these cases are also estrogen   receptor 
(ER)  and  progesterone receptor (PR) positive but HER2 negative. 
 
Invasive Medullary Carcinoma: 
Total Cases are about 1% to 2% of Breast carcinoma. Mostly 
seen in young women with well circumscribed mass with no 
calcification. Microscopically, syncytial growth pattern with pushing 
borders with higher nuclear grade. Lymphoplasmacytic infiltration is 
seen. These cases are mostly triple negative ( ER, PR, HER2 
negative). 
 
Invasive micropapillary Carcinoma:  
(1 % to 2%) Tumor clusters are seen within empty places with 
reverse polarity. Fibrovascular core is not seen.  It expresses variable 
estrogen   receptor (ER)  and  progesterone receptor (PR) and HER2 
reactivity. 
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Metaplastic Carcinoma:  
Incidence is less than 1% of the malignant breast tumors. 
Grossly the tumor is very large in size. Microscopically, tumors are 
composed of nonglandular (squamous type) and mesenchymal 
elements. These tumors are mostly triple negative . [99] 
 
METASTASES OF BREAST CARCINOMA: 
Carcinoma of Breast can spread by direct invasion, by 
hematogenous route or by the lymphatic route. [81] 
Local invasion may spread normal breast parenchyma, nipple 
areolar complex, skin, underlying muscle, fascia, or to the chest wall. 
Lymphatic spread: Most commonly involved lymph nodes for 
metastasis of  breast carcinoma are the axillary N  and the internal 
mammary  LN, with the supraclavicular LN. [82 ] 
From various studies it is expecting that about 40–50% of 
clinically detectable cases of breast carcinoma shows Axillary node 
metastases.[83] Supraclavicular lymph node with axillary lymph node 
involvement is present in approximately 20% of patients of the cases. 
Supraclavicular lymph node involvement is very rare in absence of   
negative axillary metastasis.[84] The internal mammary chain is the 
second most common group of  lymph node drainage and it 
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contributes 22% of the metastatic lymph nodes of breast       
carcinoma. [85] 
The common sites involving distant metastases are the bone, 
lung , liver, adrenal gland, ovary, CNS  and  eyes. [86,87,88] Metastasis to 
abdominal cavity, gastrointestinal tract [89,90,91]  or  rarely spleen may 
also occur. [92] 
 
STAGING AND GRADING: 
TNM  staging system (T tumor; N, nodes; M metastases)  is the 
most widely used clinical staging system for breast carcinoma.[26] 
 
MICROSCOPIC GRADE: 
Most widely used microscopic grading systems for invasive 
breast carcinoma  is Bloom and Richardson grading system[27].  The 
Bloom and Richardson grading system is  based mainly on 
architectural features. Another microscopic grading system Black 
grading system,[28].   based on the degree of nuclear atypia. Since from 
the prognostic point of view  both architecture and cytology are 
important criteria, a joint grading system is proposed.[29,30]. The 
Nottingham modification of the Bloom–Richardson system includes  
the evaluation of mitotic activity along with the architectural     
features.[31] In this grading  system, the grade is obtained by the sum of 
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the scores of three characteristic features,  tubule formation, nuclear 
pleomorphism, and mitotic count. The total point after adding the 
scores 3 -5 regarded as  final grade 1, Score 6 to 7 is grade II and  
score 8 to 9 is considered as grade III. [32] 
 
MICROSCOPIC GRADING OF BREAST CARCINOMA  
(Nottingham modification of the Bloom–Richardson system) 
 
Tubule formation : 
1 point: Tubular formations in >75% of the tumor 
2 points: Tubular formations in 10–75% of the tumor 
3 points: Tubular formations in <10% of the tumor 
 
Nuclear pleomorphism : 
1 point: Nuclei with minimal variation in size and shape. 
2 points: Nuclei with moderate variation in size and shape. 
3 points: Nuclei with marked variation in size and shape. 
 
Mitotic count: 
1 point:-- mitosis 0 to 9 
2 points: -- Mitosis 10 to 19 
3 points – mitosis more than 20. 
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The total point is the sum of the three points. In this system  
Grade I (point 3 to 5) is considered as well differentiated,  Grade 2 
(point 6 to 7) Moderately differentiated and Grade 3 (point 8 to 9) 
poorly differentiated.[93] 
 
PROGNOSIS 
The prognosis of carcinoma breast depends upon multiple 
number of clinicopathological factors.[33–34] 
 
Age: 
Breast carcinoma patients aged less than 50 years at the time of 
diagnosis show excellent prognosis. Prognosis tends to  decline 
gradually with age after the age group of 50 years.[35]  Some recent 
studies have shown that prognosis among young ladies (=35 years ) is 
also not good as the older ladies.[36] 
 
  
SUM OF POINTS FINAL GRADE 
3–5 I 
6–7 II 
8–9 III 
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Invasiveness: 
Invasiveness  is a very important prognostic factor for 
carcinoma breast. In situ carcinomas may be curable with mastectomy 
because of less probability of metastasis.[37] Sometimes 
comedocarcinoma type DCIS can associate with metastases which is a 
sign of poor prognosis.. The carcinomas invading to the underlying 
skeletal muscle are difficult to do surgery. 
 
Early diagnosis: 
Early detection of cancer is a good prognostic factor. 
 
Size: 
Higher diameter of the tumor have higher chances of  nodal 
metastases and lower survival rate. It is established that microscopic 
size determination has a greater prognostic predictive value than gross 
size of the tumor. If an invasive tumor is having both in situ and 
invasive component, the size of the invasive component will be more 
important prognostic predictor than the  gross size of the tumor. [38] 
 
Cytoarchitectural type: 
Prognosis of both invasive ductal and lobular carcinoma are 
similar.[39] Some morphologic types of ductal carcinoma shows good 
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prognosis. Tubular ca, cribriform ca, medullary ca (when strictly 
defined), pure mucinous ca, papillary ca, adenoid cystic ca, and 
secretory (juvenile) ca are the variants with good prognostic 
outcome.[40,41,42] Signet ring carcinoma is associated with very bad 
prognosis.  
 
Margins: 
Tumors with infiltrating margins have a bad prognosis than 
tumors with pushing ’margins.[43,44] 
 
Tumor necrosis : 
Necrosis is associated with tumors of high histological grade 
and increased incidence of lymph node metastases.[45] So tumor 
necrosis is a sign of bad prognosis. 
 
Inflammatory carcinoma: 
In breast carcinoma cases the signs of breast erythema and skin 
thickening are  poor prognostic indicators. Most of these patients show 
evidence of distant metastasis. 
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Stromal reaction: 
Breast carcinoma with an absence of inflammatory reaction at  
periphery have a lesser chance of nodal metastases and hence these 
tumors show good prognosis.[46]  
 
Microvascular density (MVD): 
Invasive breast carcinomas with higher amount of vascular 
component are tend to be more aggressive in nature and so the 
prognosis will be poor.[47] 
 
Fibrotic focus: 
Tumors composed of a fibrotic area is a sign of hypoxia and 
lymphangiogenesis and it is unfavorable for good prognosis.[48] 
 
Skin invasion: 
Breast carcinomas with overlying skin invasion is have a poor 
prognosis.[49] 
 
Nipple invasion: 
Nipple involvement with the malignant tumor have higher 
incidence of metastases to the axillary lymph nodes.[50] 
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Tumor emboli: 
Tumor emboli are divided mainly into  two types, blood vessel 
emboli and lymph vessel tumor emboli. Malignant tumors of breast 
having blood vessel tumor emboli show poor prognostic outcome.[51] 
Similarly tumor emboli inside lymph vessels is also associated with 
high recurrence rate.[52] Intravascular tumor emboli containing 
apoptotic body and mitotic figure is a sign of bad prognosis.[53] 
 
Microscopic grade: 
The Nottingham modification of the Bloom–Richardson system 
is used for microscopic grading of breast carcinoma. Scores 3 -5 
regarded as  grade 1, Score 6 to 7 is grade II and  score 8 to 9 is 
considered as grade III. 
 
Estrogen receptors (ER): 
Several studies established that ER-positive tumors have a 
longer survival rate than the ER negative tumors.[54]  Estrogen receptor 
(ER ) and progesterone receptor (PR ) positive tumors show good 
response to hormonal therapy. 
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HER2/neu: 
Tumors with over expression of HER2/neu show good 
response to trastuzumab but a poor response to chemotherapy.[55] 
 
BCL2: 
Patients with BCL2 positive tumors show long-term survival 
rate.[56] Some recent studies shows a correlation between BCL2 
positivity and ER positivity in breast carcinoma.[57] 
 
BRCA1 status: 
From previous studies it is  thought that breast carcinomas with 
BRCA1 mutation carriers a poor survival rate, without receiving 
adjuvant therapy,[59] but some recent studies show  that breast cancer 
patients with either  BRCA1 or BRCA2 mutations have same prognosis 
as the non-carriers. [58] 
 
Cell proliferation:  
Cell proliferation index is a very important prognostic 
indicator,[60] particularly for the cases with metastasizing to lymph 
nodes. It is determined by mitotic count,[61] by Ki-67 or analogous 
immunostaining.[62] High proliferative index tumors show poor 
prognostic outcome. 
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Metastases to axillary lymph node:   
Axillary LN metastasis is an important prognostic parameter for 
breast carcinoma.[63] Positivity of the axillary lymph node status 
indicates poor  prognosis. During histological study of nodal status of 
carcinoma breast, the  level of  involvement either  low, or high[64] the 
number of node involved,[65] the amount of the tumor component in 
the node,[66] status of extra-nodal spread ,etc should be examined 
thoroughly.[67] 
 
Distant metastasis: 
Presence of distant metastasis is a very poor prognostic 
indicator. 
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HORMONE RECEPTORS 
Both estrogen receptor (ER)  and progesterone receptor ( PR)  
are located in the nucleus of the cells. The Hormone estrogen and 
progesterone are transported to the nucleus and forms hormone – 
receptor complex. It is believed that the ER and PR  receptors regulate 
some genes which  control growth of cells. Therefore Estrogen 
receptor status is important in breast cancer for therapeutic target to 
inhibit the growth of tumor that influenced by estrogen. 
Estrogen Receptor was discovered in the 1960s. From several 
studies it is established that ER status is effective to manage the 
growth of the ER positive tumors by  endocrine targeting inhibition of 
the receptor. The inhibition of ER can be done such by selective ER 
modulators therapy or by aromatase inhibitors or              
oophorectomy etc.[68] 
The status of hormone estrogen and progesterone receptors 
positivity  is a very important indicator for hormone therapy and 
chemotherapy in breast carcinoma cases. Among these two, the  
estrogen receptor(ER) positivity status is considered as a very useful 
marker to predict the response to hormonal therapy or 
chemotherapeutic management of breast carcinoma[69] 
 
31 
 
These hormone ER and PR  receptor status is  measured by 
immunohistochemical staining method. Other methods to detect the 
hormone receptor are dextran-coated charcoal & sucrose gradient 
assay .[70], situ hybridization technique and by PCR.[71] 
In immunohistochemical study two parameters are evaluated, 
first one the number of tumor cell nuclei stained with the marker ,and 
secondly the intensity of the reaction. 
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HER 2 NEU 
Human epidermal growth factor (HER 2)gene in malignant 
breast tumor was discovered  in 1987. The gene was originally termed 
as NEU because it was first recognized in  neuroblastoma / 
glioblastoma tumor cell lines of rat.[68] Approximately 15% to 20% of 
breast cancer cases show HER2 positivity and it is an indicator of poor 
prognostic outcome of chemotherapy and hormonal therapy.[68] 
The breast cancer patients with positive HER2 NEU 
immunohistochemistry have worse prognosis in absence of adjuvant 
systemic therapy. It is also established from Several studies that  
HER2-neu overexpressing tumors have relative resistance to endocrine 
therapy such as tamoxifen,[72] 
Many other organs like ovary, uterus, stomach, colon, urinary  
bladder, prostatic gland, salivary gland etc also show over expression 
of HER 2 NEU gene. 
The prognostic importance of HER 2 NEU positivity in breast 
carcinoma is variable among several studies. 
Even some studies (Slamon DJ, Clark GM, Wong SG) shows 
that, HER-2/neu expression status have more prognostic importance  
than other  prognostic factors like ER, PR receptor positivity  status  in 
lymph node-positive breast cancer cases.[73] 
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Some other studies found HER-2 neu expression in breast 
carcinoma have  inverse prognostic  relationship with both ER and PR 
positivity status. According to these studies HER 2 neu positive cases 
have  relative resistance to endocrine  therapy.[74] 
Several  clinical trials show that it is effective to  use  anti–
HER-2 agents therapy  in patients with HER-2–expressing  breast 
cancer.[75,76] 
 
Grading of the immunohistochemical staining for HER2-neu 
STAINING PATTERN SCORE ASSESSMENT 
No staining  / Or 
membrane staining in < 10% 
of the tumor cells 
0 Negative 
A faint  membrane staining 
more than 10% of the tumor 
cells. 
1+ Negative 
A weak to moderate complete 
membrane staining in more 
than 10% of the tumor cells 
2+ Weakly positive 
A strong complete membrane 
staining is more than 30% of 
the tumor cells 
3+ Strongly positive 
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MOLECULAR SUBTYPES OF BREAST CANCER BASED ON 
ER, PR AND HER 2 NEU STATUS: 
Along with the clinical behavior and histopathological 
classification of malignant tumors of breast, the molecular 
classification is also very important to access prognosis and for 
appropriate therapy . The major molecular subtypes of  Ca breast 
cancer determined by gene expression of ER , PR and HER2.[80] 
In this classification carcinoma breast cases are divided into 4 
major subclasses, Luminal A, Luminal B, HER2/neu and               
Basal-likea  [32] 
 
Luminal A - 
ER and/or PR positive, HER2 negative. (most common subtype. 
50% of invasive breast cancers are Luminal A type). 
Most of the older women and men patients belong to this group. 
 
Luminal B - 
ER and/or PR positive, HER2 positive/ negative.             
(Second most common type ~20% of invasive breast cancers). 
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HER2/neu  -  
ER negative PR negative, HER 2 positive. (~15% of invasive 
breast cancers). Approximately  50% of patients of HER 2 positive 
group shows ER positivity. Most common patients  in this group are 
young  ladies. 
 
Basal like or triple negative breast cancers - 
ER negative, PR negative, HER 2 negative.(~15% of invasive 
breast cancers) 
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GATA 3 
The GATA family of transcription factor consists of 6 
transcription factors (GATA-1 to GATA-6) characterized  by ability to 
bind with the “GATA” sequence of DNA . GATA transcription factor 
regulates differentiation of various tissue types, including mammary 
gland, T lymphocytes, kidney, nervous system and hair follicle. 
Although GATA 3 is expressed in many tissues, but it is not always 
detectable by immunohistochemical staining due to its low level in the 
tissue. [77] 
Therefore, some publications say that mutation of genes 
encoding  GATA family of transcrtption factors may have  role in the 
development of various types of cancers in human body. [78] 
Many malignant tumors of GIT, ovary, lung,  and brain show 
altered expression of GATA 4, GATA 5, and GATA 6. [78]  Various 
studies established that GATA 3 is a high specific marker for breast 
carcinoma and carcinoma of urothelium.[77] 
GATA 3 expression in breast carcinoma is established from 
several studies but few important points are still not clear about the 
clinical use of immunehistochemical study of GATA 3. 
1. Several studies suggest that GATA3 is expressed more 
commonly in ER positive tumors than ER-negative tumors.[79] 
But GATA 3 expression in triple negative (ER,PR, HER2 
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negative cases ) tumor  is most relevant to prove whether the 
tumor is from mammary origin or not. [77] 
2. Positivity of GATA 3 in metaplastic (sarcomatoid ) carcinoma 
is not studied to distinguish it from other spindle cell 
malignancies in the breast. 
3. Clinically GATA 3 can be used as a marker to diagnose the 
metastatic tumors originating from breast. [77] 
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MATERIALS AND METHODS 
This is a study of  both prospective and retrospective type of 
data analysis of patients diagnosed as  invasive breast carcinoma in 
Institute of Pathology, Madras Medical College and Rajiv Gandhi 
Government General Hospital, Chennai. Our study period was 3 years 
(June 2015 to may 2018). 
For our study, we randomly selected  50 cases of invasive breast 
carcinoma with already known ER , PR and HER 2 NEU status . The 
slides are prepared from formalin fixed paraffin embedded archived 
tissue blocks of tru-cut biopsy and mastectomy specimens. The 
biopsies were processed for light microscopy with routine 
haematoxylin and eosin stain. Immunohistochemistry was done as per 
standard protocol. 
 
IMMUNOHISTOCHEMICAL EVALUATION: 
Immunohistochemical analysis of GATA 3 was performed in 
paraffin embedded tissue blocks by using polymer HRP system. The 
thickness of the  sections were 4 micron prepared (cut) with 
microtome from formalin fixed paraffin embedded tissue block 
samples and transferred onto positive charged slides. Heat induced 
antigen retrieval was done as per procedure . The antigen was bound 
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with monoclonal antibody (Pathnsitu) against GATA 3 protein, then 
detected by adding secondary antibody. 
 
 
INCLUSION CRITERIA: 
Breast carcinomas with known ER,PR and HER 2 NEU status 
in tru-cut biopsy and mastectomy specimens. 
EXCLUSION CRITERIA: 
1. Benign lesions of Breast. 
2. Insufficient representative material. 
3. Breast carcinoma cases with unknown ER, PR and HER 2 NEU 
status. 
4. Lack of paraffin blocks with representative tumor tissue was 
excluded from the study population 
 
  
ANTIGEN VENDOR SPECIES (CLONE) DILUTION 
POSITIVE 
CONTROL 
GATA 3 PATHNSITU Mouse monoclonal 
Ready to 
use 
Urothelial 
Carcinoma 
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METHOD OF DATA COLLECTION 
The clinical data are collected from surgical pathology records 
of Institute of Pathology, Madras Medical College, Chennai. Age, Sex,  
size of the tumor, surgical procedure, gross findings of the tumor, 
microscopic findings on  hematoxylin and eosin (H&E) stained 
histopathological examination, status of the estrogen receptor (ER) 
,progesterone receptor (PR) and HER-2  immunohistochemistry 
reaction are collected from both the registers of routine biopsy and 
immunohistochemistry record. 
 
INTERPRETATION AND SCORING SYSTEM: 
The slides immunohistochemically stained with GATA 3 
marker were analyzed for the positivity or negativity of the antibody 
reaction, staining pattern, percentage of cells that stained with the 
reaction  and intensity of the reaction. Any intensity with more than 
5% of cells showing positive staining for GATA3  is considered as 
positive . 
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Scoring: 
GATA3 is a nuclear marker and its reactivity is scored as 0 to 4 
+ according to the percentage of cells stained. The extent of nuclear 
reactivity is graded as follows - 
Score 0 = (0- 5%) less than or equal to 5% of positively staining tumor 
cell considered as negative. 
Score 1+ = 6% to 25 % cells positive. 
Score 2+ = 26% to 50% cells Positive. 
Score 3+ = 51% to 75% cells Positive. 
Score 4+ = More than 75 % cells are positive. 
 
Intensity: 
Intensity of staining is recorded as weak, moderate or strong. 
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STATISTICAL ANALYSIS 
The statistical evaluation was performed with Microsoft office 
excel software system.  Initial data from the histopathology register is 
collected and compared with the findings of the GATA 3 
immunohistochemical analysis of the cases. The GATA 3 expression 
was compared and correlated with clinicopathological data like age, 
sex, size of the tumor, lymph node status etc. Pearson Chi square test 
was also used to analyze these data.  In our  study, the P value less 
than 0.05 is considered significant. 
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OBSERVATION AND RESULTS 
During our study period from June 2015 to May 2018 (3 years) 
we studied the malignant tumors of breast both in Prospective and 
retrospectively. We studied total 50 specimens of   Carcinoma breast 
diagnosed by histopathological examination  in the Institute of 
Pathology, Madras Medical College and Rajiv Gandhi Govt General 
Hospital- Chennai. The specimens were selected randomly from the 
formalin fixed archived tissue blocks. The status of  ER, PR and HER 
2 neu reactivity is already known for all these cases. Out of these 50 
cases 45 specimens obtained from  MRM (Modified Radical 
Mastectomy), one case breast conservative surgery, one excision 
Biopsy, two tru-cut biopsy and one wide local excision specimen. 
Procedure Number of specimen 
MRM (Modified Radical Mastectomy) 45 
Breast conservative surgery 1 
Wide Local Excision 1 
Excision Biopsy 1 
Tru-cut biopsy 2 
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GENDER: 
Out of the 50 cases, 49 were female patients and one male. The 
patient was 55 years male histologyically diagnosed as invasive breast 
carcinoma – no special type , Grade II. 
SEX NUMBER OF CASES 
Female 49 
Male 1 
 
AGE WISE INCIDENCE OF BREAST CARCINOMA: 
In this study, age of the patient was divided into 6 groups as less 
than 30 years, 31-40 years, 41-50, 51-60, 61-70 and above 70 years. 
Age wise incidence of breast carcinoma cases were as follows. 
Age group Number of Cases 
Less than 30 3 
31 to 40 10 
41 to 50 19 
51 to 60 13 
61 to 70 4 
71 + 1 
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6
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12
14
16
18
20
less than 
30
31 to 40 41 to 50 51 to 60 61 to 70 above 70
incidence of Ca breast with age 
incidence of Ca breast 
Chart: incidence of breast carcinoma in relation to age. 
 
In our study the peak incidence of breast carcinoma is 41 to 50 
years of age. Carcinoma of breast is rare below the age of 30 years. 
 
GATA 3 SCORING : 
Among these 50 cases of breast carcinomas, total 36 cases 
(72%) are GATA 3 positive and 14 Cases (28%) GATA 3 negative. 
Out of 36 positively stained, 6 cases score 1+, 5 cases score 2+, 11 
cases score 3+ and 14 cases score 4+ . 
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GATA3 +VE
72%
GATA 3 _VE
28%
Expression of GATA 3
 
Chart: GATA3 positive cases 72%, negative 28% 
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score 1+
17%
score 2+
14%
score 3+
30%
score 4+
39%
GATA3 SCORING IN POSITIVE CASES 
 
Chart : GATA3 positive cases with scoring, 1+, 2+, 3+ and           
4+ cases 
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GATA3 expression with AGE 
In this study, under 30 years, out of 3 cases 2  showed positivity 
to GATA 3. For the age 31 to 40 years, total 8 cases of  out of total 10 
. For the age group 41 to 50, total 12 were GATA3 positive out of 19 
cases. For 51 to 60 (10 GATA3 positive out of 13), 61 to 70 (5 
positive out of 4) and above 70 years 1 positive out of one. 
 
Age GATA3 positive GATA3 negative 
<30 2 1 
31-40 8 2 
41-50 12 7 
51-60 10 3 
61-70 3 1 
70-80 1 0 
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Chart: showing correlation of GATA3  expression and age: 
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score 1+
score 2+
score 3+
score 4+
0
1
2
3
4
5
6
7
<30 31-40 41-50 51-60 61-70 71-80
score 1+
score 2+
score 3+
score 4+
GATA3 SCORING WITH AGE 
Among the positive cases of GATA3 , number of  cases with 
scoring is as follows. 
Age Score 1+ Score 2+ Score 3+ Score 4+ 
<30 years 0 0 2 0 
31 to 40 
years 2 1 3 2 
41 to 50 0 2 3 7 
51 to 60 3 0 3 4 
61 to 70 0 2 0 1 
71 to 80 1 0 0 0 
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GATA3 +VE
GATA3 -VE
0
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10
15
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30
35
female Male
GATA3 +VE
GATA3 -VE
GATA 3 expression with Gender : 
Out of 50 cases number of female patient was 49, and number 
of male patient was one. 
Sex Positive Negative 
Female 35 14 
Male 1 0 
 
Chart : GATA3 expression with Gender. 
From this study, we observed that immunohistochemical 
expression of GATA 3 in breast carcinoma was not affected by 
gender. 
52 
 
0
5
10
15
20
25
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positive
negative
GATA3 EXPRESSION WITH TUMOR SIZE (MAXIMUM 
DIAMETER): 
We divided the gross size of the tumors in four groups. First 
group is the tumors less than equal to 2.5 cm in maximum diameter 
,second group 2.6 to 5 cm, third  5.1 to 7.5 cm and forth group   7.6 
cm or more. 
Size of the tumor GATA 3 positive GATA 3 negative 
less than or equal 2.5 10 6 
2.6 to 5 cm 22 8 
5.1 to 7.5 cm 2 0 
7.6 cm or more 2 0 
 
Chart: GATA3 expression with tumor size. 
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GATA 3 EXPRESSION WITH MICROSCOPIC VARIANT : 
In our study majority of the cases were invasive breast 
carcinoma, no special type (IBC-NST) contributing 47 cases out of 
total 50 cases. Other variants were papillary variant, medullary 
differentiation, and apocrine differentiation representing one case from 
each. 
 
HISTOLOGIC 
TYPE 
GATA3 POSITIVE 
CASE 
GATA3 NEGATIVE 
CASES 
IBC – NST 34 13 
Invasive Papillary 
Type 1 0 
Medullary 
Differentiation 0 1 
Apocrine 
Differentiation 1 0 
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IBC _NST INVASIVE 
PAPILLARY
MEDULLARY 
DIFFERENTIATION
APOCRINE 
DIFFERENTIATION
34
1 0 1
13
0 1 0
GATA3 expression with histologic subtype
GATA3 +ve GATA 3 -ve
 
 
From the study we got the evidence that majority  of the IBC-
NST (invasive breast carcinoma no special) type shows reactivity to 
GATA 3 marker. Here we got 72.34%  cases of IBC- NST are    
GATA 3 positive. Invasive papillary and apocrine variant also shows 
positivity to GATA 3.  The medullary differentiation case did not 
show reaction to the marker. 
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GATA 3 EXPRESSION WITH MODIFIED BLOOM 
RICHERDSON GRADING SYSTEM FOR BREAST 
CARCINOMA: 
From the histopathological data and the microscopic 
examination of H & E slides the population of  histological grade   
were  Grade I ( total 8 case) , of grade II ( total 36 cases ) and Grade 
III ( total 6 cases). 
 
Histologic grade GATA 3 +ve GATA3 –ve 
Grade I 7 1 
Grade II 26 10 
Grade III 3 3 
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Chart GATA 3 expression with the histological grade of the 
tumors: 
 
From our study we observed that the GATA 3 is expressed in 
all the 3 grades of  Modified Bloom Richardson grading system. Our 
study concludes that the expression of GATA 3 is independent of  
histological grade of the tumour. 
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GATA 3 EXPRESSION WITH MOLECULAR SUBTYPES IN 
OUR STUDY BASED ON ER, PR AND HER 2 NEU STATUS: 
In our study the the number of molecular subtypes as follows. 
 
Subtype 
 
ER , PR, HER 2 status 
 
Number of 
cases 
Luminal ER +ve and/or PR+ve, HER2 +ve/-ve 
22 
 
HER2/neu ER PR -ve or(-ve) , HER 2 positive 14 
Basal-like 
 ER (-ve) ,PR(-ve)  HER 2 (-ve) 14 
 
Chart: Molecular subtypes of breast ca cases in our study 
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GATA3 expression with ER status. 
The correlation between GATA3 and ER in our study is 
observed as follows. 
GATA3 ER NUMBER OF CASES 
Positive (+) Positive (+) 17 
Positive (+) Negative (-) 19 
Negative (-) Positive (+) 1 
Negative (-) Negative (-) 13 
 
Chart  : GATA3 expression in relation with ER 
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GATA -VE 
9%
GATA3 expression in luminal type
GATA 3 expression with luminal type: 
In our study total 22  cases were luminat type . Out of these, 20 
show GATA3 expression and 2 case show non- reactive to GATA3. 
 
Chart: GATA3 expression with luminal type cases. 
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GATA3 positive  scoring in  luminal type: 
The GATA 3 scoring among the luminal type cases  are. As 
mentioned before we considered Score 0 or negative when the 
positively staining tumor cell less than or equal to 5%  of the total 
tumor cells. 
Score 1+ = 6% to 25 % cells positive.   Score 2+ = 26% to 50% cells 
Positive . 
Score 3+ = 51% to 75% cells Positive.  Score 4+ = More than 75 % 
cells are positive 
 NUMBER OF CASES 
SCORE 1+ 6 
SCORE 2+ 3 
SCORE 3+ 5 
SCORE 4+ 6 
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Chart: The GATA 3 scoring among the luminal type 
 
From this study we found that most of the luminal type of the 
tumors express GATA3 .It was evident that luminal tumors can 
express any score of among the  GATA 3 positive cases. 
. 
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IMMUNOHISTOCHEMICAL EXPRESSION WITH HER 2 
NEU : 
In this study total 30 (60%) cases are HER 2 neu positive and 
20 (40%) cases are HER 2 neu negative. Out of these positive cases 2 
showed 1+ score, 11 showed 2+, and 17 showed 3+. 
 
Chart: HER 2 neu expression 
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EXPRESSION OF GATA 3 WITH HER 2 NEU EXPRESSION. 
The GATA3 expression in relation with HER2 neu is as follows. 
 CASES 
GATA3 +VE, HER2 +VE 25 
GATA3 +VE, HER2 -VE 11 
GATA3 -VE, HER2 +VE 5 
GATA3 -VE, HER2 -VE 9 
 
 
 
 From our study we observed that expression of  GATA3 is 
independent  to HER 2 neu expression. 
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Series 1
GATA 3 EXPRESSION WITH HER 2 SUBTYPE OF BREAST 
CARCINOMA: 
In our study total 14 numbers (28%) of cases were HER 2 
subtype. This subtype composed of Positive HER2 but  ER expression 
may or may not be present. Among the 14 cases, 4 cases were GATA 
3 negative and 10 cases were GATA3 positive. 
 
 
 
 
 
Chart : GATA3 expression with HRE 2 subtype 
     From the study we observed that degree of  expression of    GATA 
3 is not significantly correlated with the expression of HER 2 neu. 
GATA3  scoring Number of cases of HER 2 subtype 
Negative 4 
Score 1+ 0 
Score 2+ 2 
Score 3+ 3 
Score 4+ 5 
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Series 1GATA3 
negative score 1+ score 2+
score 3+
score 4+
8
0 0
3 3
ER, PR HER 2 negative cases
Series 1
GATA 3 EXPRESSION IN (BASAL LIKE )TRIPLE NEGATIVE 
CASES 
Among these cases total 14 cases were found to be non reactive 
to ER, PR and HER 2 neu.( BASAL LIKE ). Out of these 8 of the 
triple negative cases show non reactive to GATA3 also. None of the 
cases shown GATA3 score 1+ and 2+. The remaining 3 positive  cases 
shows GATA3 score 3+ and  another 3(21.5%)  cases score 4+. 
GATA 3 Negative among triple negative cases =8  (57%) 
Number of cases GATA 3 Scoring 1+ and 2+ nil. 
 Positive scoring 3+ cases 3 (21.5%) and 4+ case = 3 (21.5%) 
Chart : GATA3 Expression in Triple Negative Cases 
  
It was found that majority (57%)  of the triple negative (basal 
like) cases do not express GATA3. 
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COLOUR PLATES 
 
 
 
 
 
 
 
 
 
FIG: invasive breast carcinoma, papillary variant 
 
 
 
 
 
 
 
 
 
 
IHC for Estrogen Receptor: 90% positive ( 5+3) 
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Photo: IHC for Progesteron Receptor ( PR)- 90% positive ( 5+3) 
 
 
  
HER 2: showing positive staining (3+) 
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Case : Invasive Breast Carcinoma, No special type:- Sheets of 
Malignant epithelial cells with eosinophilic cytoplasm, Pleomorphic 
hyperchromatic nuclei, with areas of necrosis. 
 
 
 
 
 
 
 
 
 
10x 
 
 
 
 
 
 
 
 
40x 
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ER: showing positive staining in 80% of tumor cells 
 
 
 
 
 
 
 
 
 
PR : Positivity in 80 % of tumor cells 
 
70 
 
GATA 3 : It is a nuclear marker, 70 % tumor cells shows positive 
staining. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GATA3: staining 60 % of the tumor cells . Score (3+) 
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GATA3 : Staining 90% of the tumor cells (score 4+) 
 
 
 
 
 
 
 
 
 
 
GATA3 : staining 90% of the tumor cells .(score 4+) 
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GATA 3 staining 80% of the tumor cells. Score (4+) 
 
 
 
 
 
 
 
 
 
GATA 3 staining more than 90 % of the tumor cells  
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DISCUSSION 
Invasive breast carcinoma is the most common carcinoma 
among women. According to World Health organization 22% of the 
female cancer cases are Carcinoma of breast. [95] 
According to the Indian cancer registry data Ca breast is the 
most common malignant tumor among the Indian women. In India, the 
rate of incidence is 25.8 per 100,000 women. Mortality from breast 
cancer is higher in rural areas than urban  areas of India. [3] Carcinoma 
of breast is  rare in women below 25 years of age but, after  30 the 
incidence increases rapidly.[94] 
Breast carcinomas with ER and PR positive status  have excellent 
response to hormonal therapy but  HER-2 positive cases are associated 
with poor prognostic outcome. Now-a-day’s immunohistochemical 
analysis is necessary for proper diagnosis, prediction of prognosis and 
management of breast carcinoma. 
GATA  is a transcription factor that regulates the lineage of 
differentiation of many tissue types. GATA-3 is responsible for 
differentiation of luminal epithelial cells of breast and development of 
normal breast. Studies show that recurrent somatic mutation of GATA 
3 gene is responsible for development of human breast  cancers .[96] 
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It is expected that GATA-3 expression may have prognostic 
value in invasive breast carcinoma management. Some published 
literature has proposed that GATA-3 expression is limited to 
carcinoma of breast and urinary bladder. Therefore GATA-3 may be a 
sensitive and specific marker for metastatic breast carcinoma        
cases.[96,98] 
In this study we evaluated the status of GATA3 expression in 
randomly selected Breast carcinoma specimens. Our sample size was 
50 cases of invasive breast carcinoma with already known estrogen 
receptor (ER), progesterone receptor (PR) and HER 2 status. 
Among these 50 breast carcinoma cases 49 female and one male 
patient of invasive breast carcinoma. The patient was 55 years male 
histologyically diagnosed as invasive breast carcinoma – no special 
type, Grade II. Though carcinoma in male breast is a very rare, but as 
being a tertiary referral center, it is occasionally encountered in our 
institute. 
 
TYPE OF SPECIMEN RECEIVED: 
Among the 50 specimens 45 cases were MRM (modified radical 
mastectomy), two cases of trucut biopsy,  one breast conservative 
surgery, one  wide local excision and one excision biopsy. 
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AGE WISE INCIDENCE OF CARCINOMA BREAST: 
From our study we experienced that breast carcinoma below the 
age of 30 years is a rare finding. After 30 years the incidence is 
increases with age . We found that  the peak incidence of breast 
carcinoma is 41 to 50 years of age.  Majority of the patients of breast 
carcinoma are above the age of 40 years.  The age wise incidence is 
relevant to other studies conducted in this field. 
 
EXPRESSION OF GATA3: 
In our study out of 50 cases 36 (72%) showed GATA 3 reactive 
and 14 cases (28%) cases were non reactive to GATA 3. Among the  
36 positively stained 6 cases scored 1+, 5 cases scored 2+, 11 cases 
scored 3+ and 14 cases scored 4+ . (The Scoring of GATA3 is based 
on percentage of neoplastic cells taking the stain).  In a study on 
GATA 3 expression in Breast carcinoma  conducted at the Depertment 
of Pathology , The John Hopkins Hospital, Baltimore showed that 
overall in 67 % of breast carcinoma cases express GATA 3.[96]  
Another study conducted at Osaka University Graduate School of 
Medicine Showed that 74% of the Breast carcinoma cases expresse  
GATA3.[99] 
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GATA3 EXPRESSION WITH AGE 
In this study the distribution of GATA 3 expression is showing 
in all age groups. Similarly, GATA 3 nonreactivity is also present in 
all age groups among the study population. We divided the  positive 
cases into 4 categories , Score 1+ = 6% to 25 % cells positive, Score 
2+ = 26% to 50% cells Positive. Score 3+ = 51% to 75% cells 
Positive. and Score 4+ = More than 75 % cells are positive. From the 
study we found some evidence that there is variable expression of 
GATA3  among each age group and its expression is independent of 
this variable. 
 
GATA 3 EXPRESSION WITH GENDER: 
Among all the 49 female patients 35 (71.42%) showed GATA 3 
positivity. One male patient also showed reactivity to GATA 3. 
On considering the gender with immunohistochemical 
expression of GATA3 ,both males and females showing positivity to 
the marker. As the distribution of cases among males and females is 
not uniform, it is not possible to come to a conclusion of  relationship 
between GATA 3 expression and gender. 
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GATA3 EXPRESSION WITH TUMOR SIZE MAXIMUM 
DIAMETER: 
In this study, the size of the tumor is grouped into 4  ranges – 1st 
group less than equal to 2.5 cm in maximum diameter ,second group 
2.6 to 5 cm, third  5.1 to 7.5 cm and forth group 7.6 cm or more. Out 
of 50 cases expression of GATA 3 was found in all  range of sizes 1st 
group (10 cases +ve) 2nd group (22 cases +ve), 3rd  group (2 cases) and 
4th  group (2 cases). We experienced that  there is variable expression 
of  GATA 3 among each size range and its expression is independent 
of  size of the tumor. 
 
GATA 3 EXPRESSION WITH MICROSCOPIC VARIANT: 
In our study majority of the cases were invasive breast 
carcinoma no special type(IBC-NST) contributing 47 cases. Other 
variants were papillary variant one case, medullary differentiation one 
case  and apocrine differentiation representing one case. Total 34         
(72.34%) cases of IBC –NST showed GATA 3 expression. Each case 
of papillary and apocrine variant also showed GATA 3 positivity. The 
medullary variant showed nonreactive to GATA 3. To establish a 
relationship between microscopic variant and GATA 3 expression a 
large number of study population is required. 
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GATA 3 EXPRESSION WITH MODIFIED BLOOM 
RICHERDSON GRADING SYSTEM FOR BREAST 
CARCINOMA: 
According to histological grade  the number of cases  were  
Grade I (total 8 case), of grade II (total 36 cases) and Grade III (total 6 
cases). In our study 7 cases  (out of 8) grade I, total 26 cases (out of 
total 36 cases) grade II and  3 cases (out of  total 6 cases)  Grade III 
showed expression of GATA 3.  It is evident that GATA 3  expression 
is independent of  histological grade of the tumour. 
 
GATA 3 EXPRESSION WITH MOLECULAR SUBTYPES, 
BASED ON ER, PR AND HER 2 NEU STATUS: 
In our study population 22 (44%)luminal cases, 14 (28%) HER2 
cases and   14 (28%) basal-like cases were seen. 
GATA3 with luminal type : 
Among the luminal subtype 91% (20 cases) showed GATA3 
expression. Only 2 cases of luminal subtype (9%) showed 
nonexpression of GATA 3. 
Out of the 20 GATA 3 positive cases of luminal type 6 cases 
scores 1+ expression, 3 cases (2+ expression), 5 cases ( 3+ expression) 
and 6 cases (4+ expression).  From this study it is evident that most of 
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the luminal subtypes express GATA-3. The percentage of cells stained 
by the marker is variable. 
GATA 3 expression with HER 2 : 
In this study total 30 (60%) cases are HER 2  positive and 20 
(40%) cases are HER 2 neu negative. Out of 30 HER 2 positive cases, 
25 (83.33%) showed GATA 3 reactivity, 5 (16.66%) cases were 
GATA3 negative. Among the 20 HER-2 negative cases 11 (55%) 
showed positive to GATA 3, and 9 (45%) showed negative reaction to 
GATA 3. 
From this data, the study suggested that GATA 3 expression is 
independent with the status of HER2 reactivity. 
 
GATA 3 EXPRESSION IN (BASAL LIKE) TRIPLE NEGATIVE 
CASES 
Among these cases total 14 cases were non reactive to ER, PR 
and HER 2 (basal like). Out of these, 8 (57%) cases show non 
reactivity to GATA3 also. The remaining 6 (42.85%) triple negative  
cases show GATA3 expression. From this data, it is evident that breast 
carcinoma may express GATA 3 in triple negative cases also. 
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SUMMARY 
 Breast carcinoma is seen most commonly in females. 
Carcinoma of male breast is rare finding. 
 Carcinoma of breast below the age of 30 years is uncommon. 
After 30 years the incidence increases. In our study maximum 
number of cases seen at 4th decade of life. 
 Majority of the breast carcinoma cases (72%) show GATA3 
expression . Only 28% of breast carcinoma cases show 
negative reaction to GATA 3 . 
 Immunohistochemical expression of  GATA 3 in breast 
carcinoma is not affected by gender. 
 Variable expression of GATA3 is seen among each age 
group.  GATA3 expression is independent of  the age. 
 We experienced that  there is variable expression of  GATA 3 
among each size range. Expression of GATA 3 is 
independent of the size of the tumor. 
 72.34%  cases of invasive breast carcinoma no special type    
(IBC –NST) showed GATA 3 expression. 
 Each case of Papillary and apocrine variant also showed 
GATA 3 positivity. 
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 The medullary variant showed nonreactivity to GATA3. To 
establish a relationship between microscopic variant and 
GATA3 expression, a large number of study population is 
required. 
 GATA3  expression is independent of  histological grade of 
the tumour. 
 Molecular subtypes, based on ER, PR and HER2 luminal 
type 44%, HER2 type 28% and   basal-like ( triple negative) 
28%  cases were seen. 
 Among the luminal subtype 91% showed GATA3 expression. 
 The percentage of cells stained by the marker is variable. 
 Among the  HER-2 negative cases, 55% showed positive to 
GATA 3, and 45%  showed negative reaction to GATA 3. 
Our study suggests GATA 3 expression is independent with 
the status of HER2 reactivity. 
 Total 57%  basal like cases show non reactive to GATA3 
also. The remaining 42.85%  triple negative  cases show 
GATA3 expression. It is evident that breast carcinoma may 
express  GATA 3 in triple negative cases also. 
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CONCLUSION 
It   is a  hospital based study and it may not represent the true 
incidence of the disease in the community. Most of the patients of 
breast carcinoma are above 40 years of age. Carcinoma of breast under 
30 years is seen rarely. Majority of the breast carcinoma cases shows 
GATA3 expression . Immunohistochemical expression of  GATA 3 in 
breast carcinoma is not affected by gender, age, size of the tumor and  
histological grading .  To establish a relationship between microscopic 
variant and GATA3 expression a large number of study population is 
required. Among the luminal subtype, 91% shows GATA3 expression 
with variable percentage of cells stained case by case. GATA 3 
expression is independent with the status of HER2 reactivity. GATA3 
expression in triple negative  cases is 42.85% . 
From the study it is found that GATA3 may not be shown to be 
a prognostic factor, but majority of the GATA 3 expressing tumors are 
luminal type which show excellent response to hormonal therapy. 
GATA 3 expression in triple negative tumors may be an important 
clue to establish this marker for  metastatic breast carcinoma (MBC). 
Further studies are needed to know the role of GATA 3 in breast 
carcinomas. 
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